Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Kenichi Harano

Prognostic Value of HER2 to CEP17 Ratio on Fluorescence in Situ Hybridization Ratio in Patients With Nonmetastatic HER2‐Positive Inflammatory and Noninflammatory Breast Cancer Treated With Neoadjuvant Chemotherapy With or Without Trastuzumab

Oncologist

English

Use of Eribulin as an Earlier-Line Chemotherapy for Patients With HER2-negative Metastatic Breast Cancer

Journal of Cancer

Oncology

2020

English

Related publications

High HER2/Centromeric Probe for Chromosome 17 Fluorescence in Situ Hybridization Ratio Predicts Pathologic Complete Response and Survival Outcome in Patients Receiving Neoadjuvant Systemic Therapy With Trastuzumab for HER2-Overexpressing Locally Advanced Breast Cancer

English

NT-proBNP Correlates With LVEF Decline in HER2-positive Breast Cancer Patients Treated With Trastuzumab

Cardio-Oncology

2019

English

PB.40. What Happens to the Ductal Carcinoma in Situ in HER2-positive Cancers Treated With Neoadjuvant Chemotherapy and Trastuzumab?

Breast Cancer Research

Cancer Research

Oncology

2014

English

Effectiveness of Neoadjuvant Trastuzumab and Chemotherapy in HER2-overexpressing Breast Cancer

Journal of Cancer Research and Clinical Oncology

English

Safety Assessment of Neoadjuvant Pertuzumab Combined With Trastuzumab in Nonmetastatic HER2-Positive Breast Cancer in Postmenopausal Elderly Women of South Asia

International Journal of Breast Cancer

English

Complete Pathological Response in Patients With Locally Advanced Cancer of Breast and Positive Her2/Neu With Neoadjuvant Chemotherapy

English

Efficacy of Neoadjuvant Therapy With Trastuzumab Concurrent With Anthracycline- And Nonanthracycline-Based Regimens for HER2-positive Breast Cancer

English

Evaluation of the Predictive and Prognostic Values of Stromal Tumor-Infiltrating Lymphocytes in HER2-Positive Breast Cancers Treated With Neoadjuvant Chemotherapy

English

Trastuzumab Plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer

New England Journal of Medicine

Medicine

2005

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Kenichi Harano

Prognostic Value of HER2 to CEP17 Ratio on Fluorescence in Situ Hybridization Ratio in Patients With Nonmetastatic HER2‐Positive Inflammatory and Noninflammatory Breast Cancer Treated With Neoadjuvant Chemotherapy With or Without Trastuzumab

Use of Eribulin as an Earlier-Line Chemotherapy for Patients With HER2-negative Metastatic Breast Cancer

Related publications

High HER2/Centromeric Probe for Chromosome 17 Fluorescence in Situ Hybridization Ratio Predicts Pathologic Complete Response and Survival Outcome in Patients Receiving Neoadjuvant Systemic Therapy With Trastuzumab for HER2-Overexpressing Locally Advanced Breast Cancer

NT-proBNP Correlates With LVEF Decline in HER2-positive Breast Cancer Patients Treated With Trastuzumab

PB.40. What Happens to the Ductal Carcinoma in Situ in HER2-positive Cancers Treated With Neoadjuvant Chemotherapy and Trastuzumab?

Effectiveness of Neoadjuvant Trastuzumab and Chemotherapy in HER2-overexpressing Breast Cancer

Safety Assessment of Neoadjuvant Pertuzumab Combined With Trastuzumab in Nonmetastatic HER2-Positive Breast Cancer in Postmenopausal Elderly Women of South Asia

Complete Pathological Response in Patients With Locally Advanced Cancer of Breast and Positive Her2/Neu With Neoadjuvant Chemotherapy

Efficacy of Neoadjuvant Therapy With Trastuzumab Concurrent With Anthracycline- And Nonanthracycline-Based Regimens for HER2-positive Breast Cancer

Evaluation of the Predictive and Prognostic Values of Stromal Tumor-Infiltrating Lymphocytes in HER2-Positive Breast Cancers Treated With Neoadjuvant Chemotherapy

Trastuzumab Plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer